Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.
Maeve Aine LoweryPublished in: British journal of cancer (2019)
Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi). However, primary and secondary resistance to these agents occurs even in this highly selected population.